An interventional study of LINKED and Group Intervention in Substance Use and HIV Prevention, sponsored by NYU Langone Health. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Substance-Related Disorders by NYU Langone Health — 3 open to participants now, 5 under way, none of them phase 3. Substance-Related Disorders · NYU Langone Health.
Among the 14 studies in Substance-Related Disorders by NYU Langone Health, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2027, is one of 8 with no phase, and was the 14th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →3 of the 14 studies in Substance-Related Disorders by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 398 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 87 across the 11 interventional studies, 56,598 across the 2 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
1 of the studies in Substance-Related Disorders by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776316NYU Langone HealthHarm Reduction Services | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Substance-Related Disorders by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study includes finalization of the LINKED social network intervention to improve PrEP and MOUD uptake among people who inject drugs (PWID) in collaboration with an Expert Advisory Board and staff (N=16) at The Sidewalk Project (TSP), followed by a Hybrid Type II cluster randomized trial of the LINKED intervention (versus an equal-attention control) among N=372 people who inject drugs, with 6- and 12-month follow-up assessment of PrEP and MOUD uptake. The investigators will also evaluate implementation outcomes to inform future sustainable implementation of LINKED in harm reduction organizations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aim 1 - Virtual Focus Group
Aim 2 - Intervention
Aim 3 - Virtual Focus Group/Surveys
Exclusion Criteria:
Aims 1 and 3:
Aim 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the LINKED arm will receive a peer change agent intervention consisting of a 3-hour workshop divided into four learning and practice modules.
Behavioral: LINKED
Participants randomized to the equal attention control group will receive a group intervention facilitated by trained study staff.
Behavioral: Group Intervention
LINKED is a theory-driven social network intervention (SNI) that leverages peer influence within the social networks of people who inject drugs (PWID) to disseminate information, encourage communication, and increase pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) uptake and persistence in harm reduction organization (HRO) settings.
Group intervention facilitated by trained study staff that supports critical thinking about what constitutes low, medium, and high risks for HIV and overdose.
Percentage of Participants with PrEP Uptake
Measured via filled PrEP prescription.
Time frame: Month 6
Percentage of Participants with PrEP Uptake
Measured via filled PrEP prescription.
Time frame: Month 12
Percentage of Participants with MOUD Uptake
Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.
Time frame: Month 6
Percentage of Participants with MOUD Uptake
Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.
Time frame: Month 12
Percentage of Participants with PrEP Adherence
Measured via urine immunoassays to test for oral PrEP.
Time frame: Month 6
Percentage of Participants with PrEP Adherence
Measured via urine immunoassays to test for oral PrEP.
Time frame: Month 12
Percentage of Participants with MOUD Adherence
Measured via urinalysis to test for metabolites for MOUD.
Time frame: Month 6
Percentage of Participants with MOUD Adherence
Measured via urinalysis to test for metabolites for MOUD.
Time frame: Month 12
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Suzan.Walters@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Suzan.Walters@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 23 months is below that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.